Literature DB >> 16224506

Systemic side effects from topical imiquimod.

Carl Hanger1, Judith Dalrymple, David Hepburn.   

Abstract

Mesh:

Substances:

Year:  2005        PMID: 16224506

Source DB:  PubMed          Journal:  N Z Med J        ISSN: 0028-8446


× No keyword cloud information.
  7 in total

Review 1.  Topical imiquimod: a review of its use in the management of anogenital warts, actinic keratoses, basal cell carcinoma and other skin lesions.

Authors:  Antona J Wagstaff; Caroline M Perry
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis.

Authors:  Lawrence Anderson; Michael Jarratt; George Schmieder; Stephen Shumack; Janelle Katsamas; Peter Welburn
Journal:  J Clin Aesthet Dermatol       Date:  2014-12

Review 3.  Pharmacological treatments for basal cell carcinoma.

Authors:  Seongmu Lee; Dinesh Selva; Shyamala C Huilgol; Robert A Goldberg; Igal Leibovitch
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Management of superficial basal cell carcinoma: focus on imiquimod.

Authors:  Beverly Raasch
Journal:  Clin Cosmet Investig Dermatol       Date:  2009-06-11

5.  Observational study of topical imiquimod immunotherapy in the treatment of difficult lentigo maligna.

Authors:  E E Craythorne; C M Lawrence
Journal:  Clin Med Oncol       Date:  2008-12-03

6.  Using topical imiquimod for the management of positive in situ margins after melanoma resection.

Authors:  Amrita S Pandit; Erik J Geiger; Stephan Ariyan; Deepak Narayan; Jennifer Nam Choi
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

7.  Local skin reactions and the onset of influenza-like signs and symptoms induced by imiquimod.

Authors:  Neal Bhatia
Journal:  JAAD Int       Date:  2022-03-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.